# Ocular Safety and Usability Study for FYB203 PFS

> **NCT06708637** · PHASE4 · COMPLETED · sponsor: **Formycon AG** · enrollment: 30 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Branch Retinal Vein Occlusion with Macular Edema
- Central Retinal Vein Occlusion with Macular Edema
- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **DRUG:** FYB203 2 mg (0.05 mL of 40 mg/mL)

## Key facts

- **NCT ID:** NCT06708637
- **Lead sponsor:** Formycon AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-20
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708637, "Ocular Safety and Usability Study for FYB203 PFS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06708637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*